PhRMA Urged Congress to Reauthorize Biosimilar Fee Program
Healthcare operators and manufacturers face potential shifts in regulatory review timelines for biosimilar drugs.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Should the federal government prioritize biosimilar regulation to help reduce healthcare costs for patients?
The Pharmaceutical Research and Manufacturers of America (PhRMA) has issued a formal statement calling for the reauthorization of the Biosimilar User Fee Act (BsUFA) IV. The program, which has supported the FDA's biosimilar review process since 2012, is designed to enhance efficiency and resource utilization.
Why it matters
The program remains a critical mechanism for maintaining a competitive U.S. medicines marketplace by standardizing how the FDA evaluates new biosimilar entrants. For businesses, the reauthorization directly impacts the speed of drug development cycles and the long-term availability of lower-cost treatment options.
Since its inception in 2012, the Biosimilar User Fee Act has served as the foundational funding structure for FDA review. The current proposal seeks to continue these performance goals to sustain review efficiency and market transparency.
The players
PhRMA
The Pharmaceutical Research and Manufacturers of America represents the country's leading biopharmaceutical research companies, advocating for policies that support drug development.
FDA
The Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals, including the review and approval processes for biosimilar products.
United States Congress
The federal legislative body responsible for the reauthorization of the Biosimilar User Fee Act program.
The details
The BsUFA IV agreement aims to optimize FDA review efficiency through increased communication and transparency between agency regulators and biosimilar sponsors. By providing the FDA with dedicated resources, the framework attempts to shorten development timelines for biosimilars. This operational predictability is essential for manufacturers managing clinical trial schedules and market entry strategies.
Timeline
The Biosimilar User Fee Act program was originally established in 2012.
PhRMA issued its formal statement regarding the BsUFA IV Performance Goals Letter on September 24, 2026.
Market Landscape
This push for reauthorization follows the established pattern of periodic renewal required to maintain the FDA's current regulatory review framework. It mirrors broader industry efforts to standardize FDA review protocols to improve market predictability for biosimilar developers.
Operators in the pharmaceutical and healthcare services sectors should monitor congressional activity for shifts in FDA review resource levels. Budgeting for drug development should account for the potential for either streamlined approvals or administrative delays depending on the legislative outcome.
The takeaway
The reauthorization of BsUFA IV is essential for maintaining the current pace of biosimilar reviews and market integration. Industry leaders should track the legislative progress of the reauthorization bill to assess how potential changes to FDA resource utilization may affect their long-term supply chain and development timelines.
Further reading
For context on sector regulation, see the Healthcare section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should the federal government prioritize biosimilar regulation to help reduce healthcare costs for patients?
